Edesa Biotech Inc
NASDAQ:EDSA

Watchlist Manager
Edesa Biotech Inc Logo
Edesa Biotech Inc
NASDAQ:EDSA
Watchlist
Price: 1.48 USD 2.78% Market Closed
Market Cap: $10.4m

Operating Margin

0%
Current
No historical data
Comparison unavailable

Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.

Operating Margin
0%
=
$0
/
$0

Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.

Operating Margin
0%
=
$0
/
$0

Peer Comparison

Country Company Market Cap Operating
Margin
CA
Edesa Biotech Inc
NASDAQ:EDSA
10.6m USD
Loading...
FR
Pharnext SCA
OTC:PNEXF
6T USD
Loading...
US
Abbvie Inc
NYSE:ABBV
385B USD
Loading...
US
Amgen Inc
NASDAQ:AMGN
184.4B USD
Loading...
US
Gilead Sciences Inc
NASDAQ:GILD
169B USD
Loading...
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
118.3B USD
Loading...
US
Epizyme Inc
F:EPE
94.1B EUR
Loading...
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
79.1B USD
Loading...
AU
CSL Ltd
ASX:CSL
87B AUD
Loading...
NL
argenx SE
XBRU:ARGX
43.2B EUR
Loading...
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
47.8B USD
Loading...

Market Distribution

Not Available
No Country distribution data available for this multiple

Edesa Biotech Inc
Glance View

Market Cap
10.4m USD
Industry
Biotechnology

Edesa Biotech, Inc. is a biopharmaceutical company, which focuses on acquiring, developing and commercializing clinical stage drugs for inflammatory and immune-related diseases with clear unmet medical needs. The company is headquartered in Markham, Ontario and currently employs 16 full-time employees. The company went IPO on 2008-08-25. The firm is focused on acquiring, developing and commercializing clinical stage drugs for inflammatory and immune related diseases with clear unmet medical needs. The company is organized under the laws of British Columbia, Canada. The Company’s two lead product candidates, EB05 and EB01, are in later stage clinical studies. EB05 is a monoclonal antibody therapy, which the Company is developing as a treatment for acute respiratory distress syndrome (ARDS) in COVID19 patients. ARDS is a life-threatening form of respiratory failure and the leading cause of death among COVID19 patients. ARDS can be also caused by bacterial pneumonia, sepsis, chest injury and other causes. The company is developing a secreted phospholipases A2 (sPLA2) inhibitor, designated as EB01, as a treatment for chronic allergic contact dermatitis, a common, potentially debilitating condition and occupational illness. EB01 employs a nonsteroidal mechanism of action.

EDSA Intrinsic Value
0.77 USD
Overvaluation 48%
Intrinsic Value
Price
What is Operating Margin?
Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.
Back to Top